Indian stocks: Visit www.stage2stocks.com →

Incannex Healthcare Inc.

Stage 4 · Declining · week 11→4 today

As of Oct 22, 2026, Incannex Healthcare is in Stage 4, the downtrend phase, now in its first week (since Oct 22, 2026). It closed at $2.60, 81.9% below its 52-week high and below its 200-day average, which is falling.

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. More about the company

$2.60
-6.79% today
$32.6M · Micro cap
Market Neutral — Fading

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is IXHL early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 18w
S4 14w
S4 13w
S4 30w
S4 13w
S4 19w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 18w → S1 7w → S4 6w → S1 1w → S4 14w → S1 5w → S4 13w → S1 7w → S4 30w → S1 11w → S4 13w → S1 4w → S4 19w → S1 4w → S4 12w → S1 2w → S4 1w current
Total tracked: 166 weeks across 17 stage runs.

IXHL among Drug Manufacturers - Specialty & Generic72nd of 84 by relative strength

All 84 →
Stocks in Drug Manufacturers - Specialty & Generic ranked by relative strength, with stage and one-month change
#StockStageRS1M
1CPIXStage 2 · wk 2398+6.8%
2ETONStage 2 · wk 3097−10.1%
3ANIKStage 2 · wk 1596+3.5%
4IRWDStage 3 · wk 396−16.4%
5TEVAStage 2 · wk 995+3.1%
6AMRXStage 2 · wk 1995+5.9%
7KNSAStage 2 · wk 7395+6.2%
8AMLXStage 2 · wk 1593−6.6%
…72IXHLStage 4 · wk 113−24.5%
vs 52W High
-81.9%
$2.56 lo$14.37 hi
81.9% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 1
1w13w26w
Week 1, early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-41.9%
200 DMA: $4.47 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
1.48x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-24.5%
3M
-11.9%
6M
-31.4%
YTD
-77.8%
1Y
-75.7%
Scan Membership
Not in any current scan.
Recent Stage Timeline
2026-10-22S41→4
Wk 1 · Vol 1.48x
2026-10-21S1
Wk 2 · Vol 0.36x
2026-10-20S1
Wk 2 · Vol 0.61x
2026-10-19S1
Wk 2 · Vol 0.81x
2026-10-16S1
Wk 2 · Vol 0.34x
2026-10-15S1
Wk 2 · Vol 1.02x
2026-10-14S1
Wk 1 · Vol 0.93x
2026-10-13S1
Wk 1 · Vol 0.65x
2026-10-12S1
Wk 1 · Vol 1.72x
2026-10-09S1
Wk 1 · Vol 0.50x
2026-10-08S14→1
Wk 1 · Vol 0.54x
2026-10-07S4
Wk 12 · Vol 0.30x
Moving averages & range
50 DMA
$3.27
200 DMA
$4.47
52W High
$14.37
52W Low
$2.56
5D Low
$2.60
Resistance levels (recent highs)
20d High
$3.32
60d High
$3.80
120d High
$4.91
250d High
$14.37
Next resistance
+27.7%
to 20d High
ROE
-47.8%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 0.5

Incannex Healthcare: quick answers

What stage is Incannex Healthcare in?

As of Oct 22, 2026, Incannex Healthcare (IXHL) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 22, 2026 and is in its first week there. What the four stages mean

Is Incannex Healthcare in an uptrend?

No. Incannex Healthcare is in a Stage 4 downtrend. It trades 41.9% below its 200-day average, which is falling.

How far is Incannex Healthcare from its 52-week high?

Incannex Healthcare closed at $2.60 on Oct 22, 2026, 81.9% below its 52-week high of $14.37. Its 52-week low is $2.56.

How has Incannex Healthcare performed over the past year?

As of Oct 22, 2026, Incannex Healthcare is down 75.7% over the past year and down 77.8% so far in 2026.

Which sector and industry is Incannex Healthcare in?

Incannex Healthcare is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.

About this companyHealth Care· Drug Manufacturers - Specialty & Generic

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. The company is headquartered in Melbourne, Australia.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.